PDF(Pubmed)
Abstract：
While strategies such as chemotherapy and immunotherapy have become the first-line standard therapies for patients with advanced or metastatic cancer, acquired resistance is still inevitable in most cases. The introduction of antibody‒drug conjugates (ADCs) provides a novel alternative. ADCs are a new class of anticancer drugs comprising the coupling of antitumor mAbs with cytotoxic drugs. Compared with chemotherapeutic drugs, ADCs have the advantages of good tolerance, accurate target recognition, and small effects on noncancerous cells. ADCs occupy an increasingly important position in the therapeutic field. Currently, there are 13 Food and Drug Administration (FDA)‒approved ADCs and more than 100 ADC drugs at different stages of clinical trials. This review briefly describes the efficacy and safety of FDA-approved ADCs, and discusses the related problems and challenges to provide a reference for clinical work.
摘要：
虽然化疗和免疫治疗等策略已成为晚期或转移性癌症患者的一线标准治疗方法，在大多数情况下，获得性抵抗仍然是不可避免的。抗体-药物缀合物(ADC)的引入提供了一种新的替代方案。ADC是一类新的抗癌药物，包括抗肿瘤mAb与细胞毒性药物的偶联。与化疗药物相比，ADC具有耐受性好的优点，准确的目标识别，对非癌细胞的影响很小。ADC在治疗领域占据越来越重要的地位。目前,在临床试验的不同阶段，有13种食品和药物管理局（FDA）批准的ADC和100多种ADC药物。这篇综述简要介绍了FDA批准的ADC的疗效和安全性，并探讨了相关问题和挑战,为临床工作提供参考。
